2 weeks Ago By Defense World Staff
Affimed ( NASDAQ:AFMD – Get Free Report ) will be issuing its quarterly earnings data before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.14) per share for the quarter.
Individual interested in participating in the company’s earnings conference call can do so using this link . Affimed ( NASDAQ:AFMD – Get Free Report ) last issued its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.
09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09).
Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%.
The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.67 million.
On average, analysts expect Affimed to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year. Affimed Trading Down 1.6 % NASDAQ:AFMD opened at $3.
76 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 2.
71 and a debt-to-equity ratio of 0.13. The company has a 50 day simple moving average of $3.
50 and a two-hundred day simple moving average of $4.55. Affimed has a 12 month low of $2.
92 and a 12 month high of $8.95. Wall Street Analyst Weigh In Check Out Our Latest Report on Affimed About Affimed ( Get Free Report ) Affimed N.
V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.
Featured Stories Five stocks we like better than Affimed What is a SEC Filing? Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025 What Investors Must Know About Over-the-Counter (OTC) Stocks Is Tesla’s Valuation a Bubble or Backed by Real Growth? With Risk Tolerance, One Size Does Not Fit All Trucking Stocks Led the Pack Last Week: Can They Keep Rolling? Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter ..
